{"id":"ipi-145","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Transaminitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL3039502","moleculeType":"Small molecule","molecularWeight":"416.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPI-145 selectively inhibits PI3Kδ and PI3Kγ, which are predominantly expressed in hematopoietic cells. By blocking these kinases, the drug disrupts critical survival and proliferation signals in B-cell and T-cell malignancies, leading to apoptosis and reduced tumor burden. This dual selectivity aims to minimize toxicity compared to pan-PI3K inhibitors while maintaining efficacy in lymphoid cancers.","oneSentence":"IPI-145 is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms that suppresses B-cell and T-cell signaling to reduce malignant cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:58.548Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory follicular lymphoma"},{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT04652960","phase":"PHASE1","title":"Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-21","conditions":"Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8","enrollment":38},{"nctId":"NCT03534323","phase":"PHASE1, PHASE2","title":"Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-07-12","conditions":"Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":55},{"nctId":"NCT02158091","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06-27","conditions":"Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT06522737","phase":"PHASE3","title":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","status":"RECRUITING","sponsor":"SecuraBio","startDate":"2025-05-19","conditions":"Lymphoma","enrollment":124},{"nctId":"NCT04803201","phase":"PHASE2","title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-08","conditions":"Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma","enrollment":170},{"nctId":"NCT05044039","phase":"PHASE1","title":"Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-02-28","conditions":"Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT03961672","phase":"PHASE2","title":"Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-05-13","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":15},{"nctId":"NCT04331119","phase":"PHASE2","title":"Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-07-23","conditions":"T-Cell Lymphoma","enrollment":17},{"nctId":"NCT07293403","phase":"PHASE2","title":"Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-06-07","conditions":"Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified","enrollment":25},{"nctId":"NCT04688658","phase":"PHASE1, PHASE2","title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","status":"TERMINATED","sponsor":"John Kirkwood","startDate":"2021-10-06","conditions":"Unresectable Melanoma","enrollment":13},{"nctId":"NCT05065866","phase":"PHASE1","title":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-18","conditions":"Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma","enrollment":14},{"nctId":"NCT05010005","phase":"PHASE1","title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-12","conditions":"T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia","enrollment":70},{"nctId":"NCT05057247","phase":"PHASE2","title":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","status":"COMPLETED","sponsor":"Glenn J. Hanna","startDate":"2021-10-14","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer","enrollment":26},{"nctId":"NCT07001384","phase":"PHASE1","title":"A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-08","conditions":"Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma","enrollment":30},{"nctId":"NCT06530550","phase":"PHASE2","title":"PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-10","conditions":"Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia","enrollment":51},{"nctId":"NCT06810778","phase":"PHASE1, PHASE2","title":"Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-05-02","conditions":"T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory","enrollment":12},{"nctId":"NCT02783625","phase":"PHASE1","title":"Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-05","conditions":"Lymphoma, Relapsed/Refractory T-cell Lymphomas","enrollment":114},{"nctId":"NCT03372057","phase":"PHASE2","title":"A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2018-02-22","conditions":"Peripheral T-cell Lymphoma","enrollment":156},{"nctId":"NCT04890236","phase":"EARLY_PHASE1","title":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-01-13","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":4},{"nctId":"NCT04038359","phase":"PHASE2","title":"A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2019-09-24","conditions":"Indolent Non-Hodgkin Lymphoma","enrollment":103},{"nctId":"NCT03892044","phase":"PHASE1","title":"Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma","status":"COMPLETED","sponsor":"David Bond, MD","startDate":"2019-11-05","conditions":"Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":7},{"nctId":"NCT05675813","phase":"PHASE1, PHASE2","title":"Genotype-guided Treatment in Newly Diagnosed PTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-02-13","conditions":"Peripheral T Cell Lymphoma","enrollment":264},{"nctId":"NCT05923502","phase":"","title":"(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-10-20","conditions":"Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Richter Syndrome","enrollment":200},{"nctId":"NCT02391545","phase":"PHASE1, PHASE2","title":"A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)","status":"TERMINATED","sponsor":"SecuraBio","startDate":"2014-12","conditions":"CD20+ Follicular Lymphoma","enrollment":55},{"nctId":"NCT02204982","phase":"PHASE3","title":"Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma","status":"TERMINATED","sponsor":"SecuraBio","startDate":"2014-09","conditions":"Follicular Lymphoma","enrollment":13},{"nctId":"NCT04193293","phase":"PHASE1, PHASE2","title":"A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer","status":"TERMINATED","sponsor":"SecuraBio","startDate":"2020-06-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":2},{"nctId":"NCT02004522","phase":"PHASE3","title":"A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-11","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":319},{"nctId":"NCT02049515","phase":"PHASE3","title":"A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":99},{"nctId":"NCT02711852","phase":"PHASE2","title":"A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2016-04","conditions":"Hematologic Malignancy","enrollment":19},{"nctId":"NCT01882803","phase":"PHASE2","title":"A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-06-17","conditions":"Indolent Non-Hodgkin Lymphoma","enrollment":129},{"nctId":"NCT05976997","phase":"PHASE2","title":"Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)","status":"UNKNOWN","sponsor":"Liling Zhang","startDate":"2023-05-08","conditions":"Newly Diagnosed Peripheral T-cell Lymphoma","enrollment":36},{"nctId":"NCT04487886","phase":"PHASE2","title":"Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-11-18","conditions":"COVID-19","enrollment":47},{"nctId":"NCT04372602","phase":"PHASE2","title":"Duvelisib to Combat COVID-19","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-10-12","conditions":"COVID-19","enrollment":28},{"nctId":"NCT03370185","phase":"PHASE2","title":"Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma","status":"WITHDRAWN","sponsor":"SecuraBio","startDate":"2018-02-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":""},{"nctId":"NCT02292225","phase":"PHASE1","title":"Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)","status":"TERMINATED","sponsor":"SecuraBio","startDate":"2015-02","conditions":"Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic","enrollment":3},{"nctId":"NCT04639843","phase":"PHASE1","title":"Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-03","conditions":"Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma","enrollment":""},{"nctId":"NCT05508659","phase":"PHASE1, PHASE2","title":"A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2022-09-20","conditions":"Advanced Solid Tumors","enrollment":128},{"nctId":"NCT04836832","phase":"PHASE1","title":"Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"Narendranath Epperla","startDate":"2022-07-01","conditions":"Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma","enrollment":""},{"nctId":"NCT04209621","phase":"PHASE2","title":"Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-07-31","conditions":"Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL)","enrollment":3},{"nctId":"NCT02307461","phase":"PHASE1","title":"Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2014-11","conditions":"Healthy","enrollment":103},{"nctId":"NCT02605694","phase":"PHASE2","title":"Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)","status":"WITHDRAWN","sponsor":"SecuraBio","startDate":"2015-12","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01947777","phase":"PHASE1","title":"Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-10","conditions":"Healthy","enrollment":14},{"nctId":"NCT04342117","phase":"","title":"Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL","status":"TERMINATED","sponsor":"SecuraBio","startDate":"2020-04-23","conditions":"Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin","enrollment":2},{"nctId":"NCT01925911","phase":"PHASE1","title":"Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-08","conditions":"Healthy","enrollment":14},{"nctId":"NCT01653756","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2012-07","conditions":"Asthma","enrollment":50},{"nctId":"NCT02576275","phase":"PHASE3","title":"A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)","status":"WITHDRAWN","sponsor":"SecuraBio","startDate":"2015-12","conditions":"Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma","enrollment":""},{"nctId":"NCT01836861","phase":"PHASE1","title":"IPI-145 ADME and Absolute Bioavailability Study","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-03","conditions":"Healthy","enrollment":6},{"nctId":"NCT01549106","phase":"PHASE1","title":"IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2011-08","conditions":"Healthy Volunteers","enrollment":106},{"nctId":"NCT01851707","phase":"PHASE2","title":"A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":322},{"nctId":"NCT01476657","phase":"PHASE1","title":"A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies","status":"TERMINATED","sponsor":"SecuraBio","startDate":"2011-10","conditions":"Hematologic Malignancies","enrollment":210},{"nctId":"NCT02095587","phase":"PHASE1","title":"Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2014-03","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT04707079","phase":"PHASE2","title":"A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-12-18","conditions":"Follicular Lymphoma","enrollment":24},{"nctId":"NCT04379167","phase":"PHASE2","title":"A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma","status":"UNKNOWN","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2020-12-30","conditions":"Follicular Lymphoma","enrollment":140},{"nctId":"NCT04049929","phase":"PHASE1","title":"A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2019-08","conditions":"Advanced Solid Tumor","enrollment":50},{"nctId":"NCT03757000","phase":"PHASE1","title":"A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies","status":"UNKNOWN","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2017-12-25","conditions":"B-cell Lymphoma Recurrent, B-cell Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT02598570","phase":"PHASE1","title":"Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT02640833","phase":"PHASE1","title":"A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2016-07","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT01871675","phase":"PHASE1","title":"Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2013-05","conditions":"Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma","enrollment":48},{"nctId":"NCT02028039","phase":"PHASE2","title":"IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12","conditions":"Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"ENTERITIS INFECTIOUS"},{"count":5,"reaction":"DEHYDRATION"},{"count":5,"reaction":"DIARRHOEA"},{"count":4,"reaction":"STOMATITIS"},{"count":3,"reaction":"DYSPNOEA"},{"count":3,"reaction":"GASTRITIS"},{"count":3,"reaction":"SEPSIS"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"CARDIAC FAILURE"}],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Duvelisib","Copiktra","PI3K Inhibitor"],"phase":"phase_3","status":"active","brandName":"IPI-145","genericName":"IPI-145","companyName":"SecuraBio","companyId":"securabio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IPI-145 is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms that suppresses B-cell and T-cell signaling to reduce malignant cell proliferation and survival. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}